Murdoch D, Shaw E, Raffel O C, Walters D L
Heart and Lung Institute, The Prince Charles Hospital, Brisbane, Australia -
Minerva Cardioangiol. 2015 Aug;63(4):343-57. Epub 2015 May 8.
Transcatheter aortic valve implantation (TAVI) is the new standard of care for selected patients with severe symptomatic aortic stenosis who are at high risk for surgical aortic valve replacement (AVR), or are inoperable. Multicentre randomised controlled trials have demonstrated equivalent or superior clinical outcomes for TAVI compared to AVR in carefully selected patient cohorts. A number of important limitations were observed with early generation TAVI valves and their delivery systems, and rapid evolution of the technology continues. The Lotus Valve System aims to address a number of these limitations - it is repositionable and retrievable, and has an adaptive seal to prevent paravalvular aortic regurgitation. Early clinical outcomes for the Lotus Valve System have recently been published with promising results in terms of paravalvular regurgitation and repositionability.
经导管主动脉瓣植入术（TAVI）是针对特定严重症状性主动脉瓣狭窄患者的新治疗标准，这些患者进行外科主动脉瓣置换术（AVR）的风险很高或无法进行手术。多中心随机对照试验表明，在精心挑选的患者队列中，TAVI与AVR相比具有同等或更好的临床结果。早期一代的TAVI瓣膜及其输送系统存在一些重要局限性，并且该技术仍在快速发展。Lotus瓣膜系统旨在解决其中一些局限性——它可重新定位和回收，并且具有自适应密封以防止瓣周主动脉反流。Lotus瓣膜系统的早期临床结果最近已发表，在瓣周反流和可重新定位方面取得了令人鼓舞的结果。
